glp 1 compounded GLP-1 Safety: Supervised Weightloss Medications Compounded GLP-1 - Semaglutide &

Several forces will shape this trajectory: Patent Expiry and Pricing: Semaglutides Loss of Exclusivity Off-patent semaglutide will be a defining event in 2026 as it begins to come off patent in several countries

This dual-action medication targets two metabolic hormones instead of one, which is clinically associated with superior efficacy and more significant weight loss outcomes for many patients

Safety Overall, 9 (69.2%) patients treated with GLP-1-RAs reported at least one AE

systematic review of 13 studies encompassing 84,065 patients demonstrated significantly higher retained gastric contents rates (odds ratio 5.56, 95% confidence interval 3.359.23) but found no significant difference in actual aspiration rates (odds ratio 1.75, 95% confidence interval 0.644.77) [37]

As shown in Scheme 27